UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling the stability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on skin, currency, and clothing

PLoS neglected tropical diseases, 2020-11, Vol.14 (11), p.e0008831

2020

Volltextzugriff (PDF)

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

Clinical pharmacokinetics, 2015-07, Vol.54 (7), p.677-690

2015

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Clinical pharmacokinetics, 2016-11, Vol.55 (11), p.1337-1351

2016

Volltextzugriff (PDF)

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin

Clinical pharmacology and therapeutics, 2018-12, Vol.104 (6), p.1182-1190

2018

Volltextzugriff (PDF)

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

The Lancet (British edition), 2012-06, Vol.379 (9835), p.2439-2448

2012

Volltextzugriff (PDF)

Repair of Horizontal Meniscus Tears: A Systematic Review

Arthroscopy, 2014-11, Vol.30 (11), p.1513-1519

2014

Volltextzugriff (PDF)

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet (British edition), 2012-06, Vol.379 (9835), p.2429-2438

2012

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib

Clinical pharmacokinetics, 2016-01, Vol.55 (1), p.33-45

2016

Volltextzugriff (PDF)

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Journal of acquired immune deficiency syndromes (1999), 2018-08, Vol.78 (4), p.465-472

2018

Volltextzugriff (PDF)

Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions

Emerging infectious diseases, 2020-09, Vol.26 (9), p.2168-2171

2020

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

Clinical pharmacokinetics, 2011-04, Vol.50 (4), p.229-244

2011

Volltextzugriff (PDF)

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine

Clinical pharmacology and therapeutics, 2018-12, Vol.104 (6), p.1191-1198

2018

Volltextzugriff (PDF)

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

PloS one, 2011-10, Vol.6 (10), p.e25974

2011

Volltextzugriff (PDF)

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function

Journal of acquired immune deficiency syndromes (1999), 2012-09, Vol.61 (1), p.32-40

2012

Volltextzugriff (PDF)

Bi-material terahertz sensors using metamaterial structures

Optics express, 2013-06, Vol.21 (11), p.13256-13271

2013

Volltextzugriff (PDF)

Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [ 14 C]-Labeled Microtracers with Separate Labeling Positions

Drug metabolism and disposition, 2023-12, Vol.51 (12), p.1607-1614

2023

Volltextzugriff (PDF)

Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Clinical pharmacokinetics, 2018-11, Vol.57 (11), p.1369-1383

2018

Volltextzugriff (PDF)

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Clinical pharmacokinetics, 2016-05, Vol.55 (5), p.605-613

2016

Volltextzugriff (PDF)

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial

The Journal of infectious diseases, 2010-03, Vol.201 (6), p.814-822

2010

Volltextzugriff (PDF)

Molecular detection of SARS-CoV-2 in formalin-fixed, paraffin-embedded specimens

JCI insight, 2020-06, Vol.5 (12)

2020

Volltextzugriff (PDF)

Larval tolerance to salinity in three species of Australian anuran: an indication of saline specialisation in Litoria aurea

PloS one, 2012-08, Vol.7 (8), p.e43427-e43427

2012

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

Antimicrobial agents and chemotherapy, 2016-09, Vol.60 (9), p.5135-5140

2016

Volltextzugriff (PDF)

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

A minute fraction of α-synuclein in extracellular vesicles may be a major contributor to α-synuclein spreading following autophagy inhibition

Frontiers in molecular neuroscience, 2022-09, Vol.15, p.1001382-1001382

2022

Volltextzugriff (PDF)

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

British journal of clinical pharmacology, 2022-07, Vol.88 (7), p.3211-3221

2022

Volltextzugriff (PDF)

1 – 25 von 448

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(337)
Mit Volltextzugriff
(339)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Modeling the stability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on skin, currency, and clothing

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Repair of Horizontal Meniscus Tears: A Systematic Review

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function

Bi-material terahertz sensors using metamaterial structures

Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [ 14 C]-Labeled Microtracers with Separate Labeling Positions

Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial

Molecular detection of SARS-CoV-2 in formalin-fixed, paraffin-embedded specimens

Larval tolerance to salinity in three species of Australian anuran: an indication of saline specialisation in Litoria aurea

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

A minute fraction of α-synuclein in extracellular vesicles may be a major contributor to α-synuclein spreading following autophagy inhibition

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

Suchergebnisse filtern